Date published: 2025-12-20

1-800-457-3801

SCBT Portrait Logo
Seach Input

Oatp-Y Inhibitors

Organic anion-transporting polypeptide (OATP) inhibitors are chemical compounds that specifically target and inhibit the function of OATPs, a family of membrane-bound proteins responsible for the transport of various organic anions across cell membranes. The OATP family includes several isoforms, such as OATP1B1, OATP1B3, and OATP2B1, which are expressed in different tissues and are critical for the uptake of a wide range of endogenous and exogenous substrates, including bile acids, hormones, and various organic acids. Oatp-Y inhibitors are a specific class of inhibitors that bind to and inhibit these transporters, thereby preventing the uptake and translocation of their substrates into cells. These inhibitors are typically characterized by their ability to interfere with substrate binding at the active site or by altering the conformational states of the transporter, which is crucial for its functionality.

The molecular structure of Oatp-Y inhibitors often features aromatic rings, halogenated groups, and other hydrophobic domains, which facilitate their interaction with the lipophilic regions of the transporter protein. These compounds can vary significantly in their specificity, with some inhibitors targeting multiple OATP isoforms, while others exhibit a high degree of selectivity toward a particular isoform. The efficacy and affinity of Oatp-Y inhibitors depend on their structural conformation, stereochemistry, and functional groups that mimic the natural substrates of OATPs. By interfering with the transport mechanism, Oatp-Y inhibitors provide valuable insights into the molecular dynamics of transmembrane transport systems and offer a tool for studying the regulatory mechanisms governing the transport of organic anions across biological membranes. These inhibitors are also key in elucidating the structure-activity relationship (SAR) of OATP proteins, offering a detailed perspective on how chemical modifications influence transporter binding and function.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

Actinomycin D may inhibit SLCO6A1 expression by interfering with RNA polymerase activity, leading to reduced transcription of SLCO6A1 mRNA.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$40.00
$82.00
$256.00
127
(5)

Cycloheximide inhibits protein synthesis, potentially reducing SLCO6A1 levels and its subsequent function in organic anion transport.

Puromycin

53-79-2sc-205821
sc-205821A
10 mg
25 mg
$163.00
$316.00
436
(1)

Puromycin integrates into protein chains during synthesis, potentially decreasing SLCO6A1 levels and its involvement in organic anion transport.

Anisomycin

22862-76-6sc-3524
sc-3524A
5 mg
50 mg
$97.00
$254.00
36
(2)

Anisomycin may inhibit SLCO6A1 expression by interfering with protein synthesis, leading to reduced levels of functional SLCO6A1 protein.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$76.00
$216.00
101
(4)

Cisplatin may modulate transcription factors involved in SLCO6A1 expression, potentially reducing the production of SLCO6A1 protein.

Etoposide (VP-16)

33419-42-0sc-3512B
sc-3512
sc-3512A
10 mg
100 mg
500 mg
$32.00
$170.00
$385.00
63
(1)

Etoposide can impact SLCO6A1 expression through its effects on DNA topoisomerase II, potentially altering the transcription of SLCO6A1.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$57.00
$182.00
$92.00
21
(2)

Camptothecin may impact SLCO6A1 expression by affecting DNA topoisomerase I, potentially altering the transcription of SLCO6A1.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$173.00
$418.00
43
(3)

Doxorubicin may affect SLCO6A1 expression through its impact on DNA and associated cellular stress responses, potentially altering SLCO6A1 expression.

Ellipticine

519-23-3sc-200878
sc-200878A
10 mg
50 mg
$142.00
$558.00
4
(1)

Ellipticine might impact SLCO6A1 expression through its effects on DNA and potential alterations in the expression of SLCO6A1.

Mitomycin C

50-07-7sc-3514A
sc-3514
sc-3514B
2 mg
5 mg
10 mg
$65.00
$99.00
$140.00
85
(5)

Mitomycin C could affect SLCO6A1 expression by causing DNA crosslinking, potentially leading to altered SLCO6A1 expression levels.